Lyft’s IPO Won’t Be Worth the Ride

0 | By Shah Gilani

There’s a magical unicorn coming our way, and we’re being offered a ride high into profitable skies if we grab its horn and jump on.

At least that’s what Lyft’s IPO bankers and early investors want us to believe.

The truth is there’s no such thing as a unicorn in real life (in business, a unicorn is a private company that investors claim is worth more than $1 billion), and Lyft isn’t any kind of highflying substitute.

What the upcoming Lyft IPO is more likely to be is a fat payday for bankers, underwriters, and especially early investors, and a bucking-off of late-to-the-party IPO share buyers.

And while Lyft may not have much higher to go, if you’re still interested in learning about IPOs, I have the perfect IPO opportunity for you

Bayer’s Weed Killer Causes Cancer – Now What?

2 | By Wall Street Insights and Indictments Staff

Bayer AG (OTC:BAYRY) is under fire now as a jury found that a man developed cancer from exposure to Roundup weed killer. This is the second case to go to trial over the allegations – and there are more than 11,000 pending lawsuits that claim the same. And according to Shah Gilani on Varney & Co. this morning, an 11% drop in stock price is only the beginning of the hardships to come for Bayer… Click here to watch.